Company commences HeartSentry clinical research collaboration with University of British Columbia
VANCOUVER, British Columbia, May 08, 2018 — Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to advise it has engaged with a dedicated research team at The University of British Columbia (“UBC”) to perform an independent analysis and validation of the investigative data generated during the course of our clinical study currently underway in California.
Founded in 1915, the University of British Columbia is a global centre for research and teaching, consistently ranked among the top 20 public universities in the world. With two main campuses, an annual operating budget of $2.5 billion brings together over 15,000 faculty and staff serving more than 60,000 students.
Lexington’s President Eric Willis notes, “As we move through the various phases of our clinical research project, the data generated by the San Francisco Bay-area Diablo Clinical Research group will undergo further analysis as a part of our commitment to scientific validity and regulatory compliance. Accordingly, we are pleased to have enlisted the expertise of the UBC cardiology research group and look forward to working with them on this project. We are excited about the potential of establishing a long-term collaboration with UBC and the broader Canadian medical research community. Additionally, we are pleased to report that our pilot clinical study at Diablo is proceeding according to plan and we are enrolling patients in the second phase of the pilot study to continue to build statistical support for HeartSentry’s endothelial function diagnosis capabilities.”
The public is invited to follow us on Facebook, Twitter and LinkedIn. To receive our newsletter and news alerts direct to your inbox, you can signup at any time on any of the signup opportunities or “contact” page of our website.
To find out more about Lexington Biosciences, interested readers are invited to visit our website and view our video featuring principal HeartSentry inventor Dr. Jonathan Maltz, Ph.D., which provides an excellent overview of our business proposition and opportunity ahead
About Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF)
Lexington Biosciences is a medical device company developing the HeartSentry, a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person’s vascular endothelium – the vital innermost lining of the cardiovascular system. Currently, the standard of care is measurement using expensive external ultrasound by a highly trained technician. The HeartSentry core technology was developed at the University of California Berkeley over a fifteen-year R&D period involving many research studies and product iterations resulting in a portfolio of multiple pending and issued patents licensed to the company. Our aim is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person’s cardiovascular health. Lexington is engaged with the US FDA and other regulatory agencies on the required product approvals for the HeartSentry. For more information about the company please visit: https://lexingtonbiosciences.com/.
On Behalf of the Board,
CEO & Director
CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
This news release contains forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
Historical Press Releases
This website contains historical and archived press releases for Lexington BioSciences Inc.. The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, Lexington BioSciences Inc.. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.